A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients

Chao Shan, Xuping Xie, Ping Ren, Michael J. Loeffelholz, Yujiao Yang, Andrea Furuya, Alan P. Dupuis, Laura D. Kramer, Susan J. Wong, Pei-Yong Shi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The potential association of microcephaly and other congenital abnormalities with Zika virus (ZIKV) infection during pregnancy underlines the critical need for a rapid and accurate diagnosis. Due to the short duration of ZIKV viremia in infected patients, a serologic assay that detects antibody responses to viral infection plays an essential role in diagnosing patient specimens. The current serologic diagnosis of ZIKV infection relies heavily on the labor-intensive Plaque Reduction Neutralization Test (PRNT) that requires more than one-week turnaround time and represents a major bottleneck for patient diagnosis. To overcome this limitation, we have developed a high-throughput assay for ZIKV and dengue virus (DENV) diagnosis that can attain the “gold standard” of the current PRNT assay. The new assay is homogeneous and utilizes luciferase viruses to quantify the neutralizing antibody titers in a 96-well format. Using 91 human specimens, we showed that the reporter diagnostic assay has a higher dynamic range and maintains the relative specificity of the traditional PRNT assay. Besides the improvement of assay throughput, the reporter virus technology has also shortened the turnaround time to less than two days. Collectively, our results suggest that, along with the viral RT-PCR assay, the reporter virus-based serologic assay could be potentially used as the first-line test for clinical diagnosis of ZIKV infection as well as for vaccine clinical trials.

Original languageEnglish (US)
Pages (from-to)157-162
Number of pages6
JournalEBioMedicine
Volume17
DOIs
StatePublished - Mar 1 2017

Fingerprint

Neutralizing Antibodies
Viruses
Assays
Neutralization Tests
Turnaround time
Microcephaly
Dengue Virus
Viremia
Virus Diseases
Luciferases
Antibody Formation
Throughput
Vaccines
Clinical Trials
Technology
Pregnancy
Polymerase Chain Reaction
Zika Virus Infection
Association reactions
Personnel

Keywords

  • Dengue virus
  • Flavivirus diagnosis
  • Neutralization assay
  • Serologic assay
  • Zika virus

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients. / Shan, Chao; Xie, Xuping; Ren, Ping; Loeffelholz, Michael J.; Yang, Yujiao; Furuya, Andrea; Dupuis, Alan P.; Kramer, Laura D.; Wong, Susan J.; Shi, Pei-Yong.

In: EBioMedicine, Vol. 17, 01.03.2017, p. 157-162.

Research output: Contribution to journalArticle

Shan, C, Xie, X, Ren, P, Loeffelholz, MJ, Yang, Y, Furuya, A, Dupuis, AP, Kramer, LD, Wong, SJ & Shi, P-Y 2017, 'A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients', EBioMedicine, vol. 17, pp. 157-162. https://doi.org/10.1016/j.ebiom.2017.03.006
Shan, Chao ; Xie, Xuping ; Ren, Ping ; Loeffelholz, Michael J. ; Yang, Yujiao ; Furuya, Andrea ; Dupuis, Alan P. ; Kramer, Laura D. ; Wong, Susan J. ; Shi, Pei-Yong. / A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients. In: EBioMedicine. 2017 ; Vol. 17. pp. 157-162.
@article{fbe483d0042a4bd39fa759cd71282e43,
title = "A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients",
abstract = "The potential association of microcephaly and other congenital abnormalities with Zika virus (ZIKV) infection during pregnancy underlines the critical need for a rapid and accurate diagnosis. Due to the short duration of ZIKV viremia in infected patients, a serologic assay that detects antibody responses to viral infection plays an essential role in diagnosing patient specimens. The current serologic diagnosis of ZIKV infection relies heavily on the labor-intensive Plaque Reduction Neutralization Test (PRNT) that requires more than one-week turnaround time and represents a major bottleneck for patient diagnosis. To overcome this limitation, we have developed a high-throughput assay for ZIKV and dengue virus (DENV) diagnosis that can attain the “gold standard” of the current PRNT assay. The new assay is homogeneous and utilizes luciferase viruses to quantify the neutralizing antibody titers in a 96-well format. Using 91 human specimens, we showed that the reporter diagnostic assay has a higher dynamic range and maintains the relative specificity of the traditional PRNT assay. Besides the improvement of assay throughput, the reporter virus technology has also shortened the turnaround time to less than two days. Collectively, our results suggest that, along with the viral RT-PCR assay, the reporter virus-based serologic assay could be potentially used as the first-line test for clinical diagnosis of ZIKV infection as well as for vaccine clinical trials.",
keywords = "Dengue virus, Flavivirus diagnosis, Neutralization assay, Serologic assay, Zika virus",
author = "Chao Shan and Xuping Xie and Ping Ren and Loeffelholz, {Michael J.} and Yujiao Yang and Andrea Furuya and Dupuis, {Alan P.} and Kramer, {Laura D.} and Wong, {Susan J.} and Pei-Yong Shi",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.ebiom.2017.03.006",
language = "English (US)",
volume = "17",
pages = "157--162",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients

AU - Shan, Chao

AU - Xie, Xuping

AU - Ren, Ping

AU - Loeffelholz, Michael J.

AU - Yang, Yujiao

AU - Furuya, Andrea

AU - Dupuis, Alan P.

AU - Kramer, Laura D.

AU - Wong, Susan J.

AU - Shi, Pei-Yong

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The potential association of microcephaly and other congenital abnormalities with Zika virus (ZIKV) infection during pregnancy underlines the critical need for a rapid and accurate diagnosis. Due to the short duration of ZIKV viremia in infected patients, a serologic assay that detects antibody responses to viral infection plays an essential role in diagnosing patient specimens. The current serologic diagnosis of ZIKV infection relies heavily on the labor-intensive Plaque Reduction Neutralization Test (PRNT) that requires more than one-week turnaround time and represents a major bottleneck for patient diagnosis. To overcome this limitation, we have developed a high-throughput assay for ZIKV and dengue virus (DENV) diagnosis that can attain the “gold standard” of the current PRNT assay. The new assay is homogeneous and utilizes luciferase viruses to quantify the neutralizing antibody titers in a 96-well format. Using 91 human specimens, we showed that the reporter diagnostic assay has a higher dynamic range and maintains the relative specificity of the traditional PRNT assay. Besides the improvement of assay throughput, the reporter virus technology has also shortened the turnaround time to less than two days. Collectively, our results suggest that, along with the viral RT-PCR assay, the reporter virus-based serologic assay could be potentially used as the first-line test for clinical diagnosis of ZIKV infection as well as for vaccine clinical trials.

AB - The potential association of microcephaly and other congenital abnormalities with Zika virus (ZIKV) infection during pregnancy underlines the critical need for a rapid and accurate diagnosis. Due to the short duration of ZIKV viremia in infected patients, a serologic assay that detects antibody responses to viral infection plays an essential role in diagnosing patient specimens. The current serologic diagnosis of ZIKV infection relies heavily on the labor-intensive Plaque Reduction Neutralization Test (PRNT) that requires more than one-week turnaround time and represents a major bottleneck for patient diagnosis. To overcome this limitation, we have developed a high-throughput assay for ZIKV and dengue virus (DENV) diagnosis that can attain the “gold standard” of the current PRNT assay. The new assay is homogeneous and utilizes luciferase viruses to quantify the neutralizing antibody titers in a 96-well format. Using 91 human specimens, we showed that the reporter diagnostic assay has a higher dynamic range and maintains the relative specificity of the traditional PRNT assay. Besides the improvement of assay throughput, the reporter virus technology has also shortened the turnaround time to less than two days. Collectively, our results suggest that, along with the viral RT-PCR assay, the reporter virus-based serologic assay could be potentially used as the first-line test for clinical diagnosis of ZIKV infection as well as for vaccine clinical trials.

KW - Dengue virus

KW - Flavivirus diagnosis

KW - Neutralization assay

KW - Serologic assay

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85014551961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014551961&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2017.03.006

DO - 10.1016/j.ebiom.2017.03.006

M3 - Article

VL - 17

SP - 157

EP - 162

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -